Abstract
Background: Neutropenic complications remain an important dose-limiting toxicity of cancer chemotherapy, associated with considerable morbidity, mortality, and cost. Bloodstream infection (BSI) is the most common complication leading to reduced dosage of chemotherapeutics and longer hospitalization. This study was aimed to determine the prevalence of BSI in neutropenic patients with solid tumours receiving chemotherapy in a tertiary care centre.
Objectives:
- To determine the prevalence of bacteremia in neutropenicpatients with solid malignancy receiving chemotherapy.
- To correlate the prevalence of bacteremia with the absolute neutrophil count of the patient.
Methods: A cross-sectional study was designed for prevalence of BSI in 150 patients with neutropenia who received chemotherapy for solid malignancies. Two samples of blood collected at one hour interval from each patient were plated onto agar plates and the isolates were identified by standard microbiological techniques and VITEK 2 identification systems.
Result: Among the 150 patients, 30(20%) patients had microbiologically documented blood stream infection. Gram positive cocci contributed to 89%(n=28) and Gram negative bacilli 11%(n=2). Among the Gram positive cocci, Staphylococcus epidermidis was the predominant isolate comprising 89.29% (n=25).The patients with documented BSI had their Absolute neutrophil count level between 560 x109/L and 730 x109/L.
Conclusion: The prevalence of bloodstream infection in patients with chemotherapy induced neutropenia was 20% and Staphylococcus epidermidis was the predominant isolate (83.3%). Hence, the Absolute neutrophil count below 1000 ×109/L in patients receiving chemotherapy should alert the treating clinician about the possible risk of bloodstream infection to reduce hospitalization and to prevent the morbidity and mortatlity associated with neutropenia.
Keywords: Neutropenia, Chemotherapy, Bacteremia, Bloodstream infection, Chemotherapy induced neutropenia, Staphylococcus epidermidis.
References
1. Holmes, F.A., Jones, S.E., O'Shaughnessy, J., Vukelja, S., George T, Savin, et al. (2002). “Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.” Annals of Oncology, 13(6), 903-9.
2. Pizzo PA. Management of Fever in Patients with Cancer and Treatment-induced Neutropenia. N Engl J Med. 1993;328:1323–32.
3. Cancer 2004;100:228–37. © 2003 American Cancer Society.
4. National Cancer Institute. Common toxicity criteria, version 2.0. Available from URL: http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf [access date January 3, 2003].
5. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR. Infectious Diseases Society of America (2011) clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011; 52: 427–431.
6. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004; 39: S327.
7. Montassier E, Batard E, Gastinne T, Potel G, de la Cochetiere MF. Recent changes in bacteraemia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J ClinMicrobiol Infect Dis. 2013; 32: 841–850.
8. Culakova, E., Thota, R., Poniewierski, M.S., Kuderer, N.M., Wogu, A.F., Dale, D.C., Crawford, J. and Lyman, G.H. (2014). “Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.” Cancer Medicine, 3(2), 434-44.
9. Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J. Natl. Compr. Canc. Netw. 2008;6:109–118.
10. Silber JH, Fridman M, DiPaola RS, Erder MH, Pauly MV, Fox KR. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J. Clin. Oncol. 1998;16:2392–2400.
11. Anatoliotaki M, Valatas V, Mantadakis E, Apostolakou H, Mavroudis D, Georgoulias V, Rolston KV, Kontoyiannis DP, Galanakis E, Samonis G. Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome. Infection.2004; 32: 65–71.
12. Schelenz S, Nwaka D, Hunter PR. Longitudinal surveillance of bacteraemia in haematology and oncology patients at a UK cancer centre and the impact of ciprofloxacin use on antimicrobial resistance. J AntimicrobChemother.2013; 68: 1431–1438.
13. Gudiol C, Bodro M, Simonetti A, Tubau F, Gonzalez-Barca E, Cisnal M, Domingo-Domenech E, Jimenez L, Carratala J. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. 2013: 474–479. Epub 2012 Apr 24.
14. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003; 36: 1103–1110.
15. Mackie, T.J. and McCartney, J.E. Practical medical microbiology.14th edition. Churchill Livingstone, New York; 1996.
16. Betty A. Forbes ,Daniel.F.Sahm, Alice S. Weissfeld Bailey & Scott’s Diagnostic Microbiology 12th edition.
Corresponding Author
Dr Yazhini K, MBBS., MD
Assistant Professor & Consultant Microbiolgist, Meenakshi Ammal Dental College & Meenakshi General Hospital
Address: No.12, Padmavathynagar, 13th cross street, Thirumullaivoyal, Chennai – 600062, India
DOI: https://dx.doi.org/10.18535/jmscr/v7i6.185
